Biosign Technologies Inc. (fka BITKF)

[Renee]

BITKF FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

BIO / BITKF one for 10 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[CarbonTrader22]

AGM video and .pdf on website:
http://www.biosign.com/investors.aspx

[in2lite]

BIO.C Analysis c/o StockTA

See: http://www.stockta.com/cgi-bin/analysis.pl?symb=BIO.C

[in2lite]

BIOSIGN TECHNOLOGIES INC
Daily Commentary: American Bulls

BUY-IF
0.3600
+0.0850 +30.91%
Candlestick Analysis
Today’s Candlestick Patterns:
White Marubozu
Bullish Engulfing

Today a White Marubozu was formed. This shows that the buyers controlled the price action from the first trade to the last trade.

The last two candlesticks formed a Bullish Engulfing Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation.
Our system posted a BUY-IF today. The previous SELL recommendation was issued on 10.25.2011 (10) days ago, when the stock price was 0.3700. Since then BIO has fallen -2.70% .

A bullish pattern has developed and a BUY-IF alert is issued today. The task is now to confirm the validity of this bullish pattern. We will guide you through this process but the prime star of this game is nobody but you. First you must do your homework. A good starting point may be to keep an eye on after-hours and futures trading to get preliminary hints about the direction of the market. Related news, events, economic data, and the world stock markets should also be closely followed prior to confirmation session.

There are three possible cases of confirmation. You have to follow the next session carefully to check if these cases will hold or not:

The market opens with an upward gap, signaling a bullish sentiment in the first case. Your benchmark will be the opening price. If the prices stay over the benchmark, go long. Any white candlestick with an upward gap is a valid confirmation criterion.

In the second case, the market opens at a level, equal to or below the previous day’s close. The benchmark is that closing price. If prices during the session stay over the benchmark, go long. Any white candlestick closing above the previous day’s close is the second confirmation criterion.

If, however, in both cases, the prices during the session start coming below the benchmark, avoid buying. Sell if you feel a definite tendency in prices to close the day below the benchmark.

The third case of confirmation is rarely observed. The market opens with a big downward gap suggesting a very bearish day, and the day ends with a long white candlestick, but still closing below the previous day’s close. However, such a day satisfies the third confirmation criterion and in this case the closing price of the long white candlestick will be taken as the price of confirmation.

If one of the three confirmation criteria is not fulfilled, or in case of a black candlestick or a doji on the confirmation day, the BUY-IF alert remains valid, however without confirmation and the three confirmation criteria are then sought in the following day. The only exception is the long black candlestick. Any long black candlestick following a BUY-IF alert makes it (the signal) void and invalid.

We do not suggest any new short positions given the bullish alert. The short sellers should consider covering their positions if the market confirms the BUY-IF signal. Otherwise, existing short positions should be carried.

Data provided by: End of Day Data

http://americanbulls.com/StockPage.asp?CompanyTicker=BIO&MarketTicker=VSE&Typ=S

[in2lite]

Health 2.0: Speaking with Dr. Scott Jenkins, CEO of Biosign

Dr. Scott Jenkins, CEO of Biosign, speaks about highlights at Health 2.0 2011 in San Francisco.

Biodesign is a medical device company whose products include "intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication."

http://www.hcplive.com/hcplive-tv/Health-20-Speaking-with-Dr-Scott-Jenkins-CEO-of-Biosign

[in2lite]

TORONTO, Nov. 3, 2011 /PRNewswire/ - Biosign Technologies Inc. (TSXV: BIO)a companyfocused on non-invasive monitoring of common health risks associated with blood pressure, glucose and medication, is providing an update on recent corporate developments.

The Company announced today that it has shifted its near term corporate strategy from a focus on R&D associated with the commercialization of the UFIT TEN-20 non-invasive blood pressure and blood glucose meter towards cash generation activities from the sale of the UFIT TEN-10 blood pressure monitor.

The UFIT TEN-10 is available for market deployment and the Company has in stock an inventory of UFIT PADs, pulse acquisition devices used in both the UFIT TEN-10 and UFIT TEN-20, with a value based on current list prices in excess of $2,500,000 from which to draw upon for customer orders.

The worldwide regulatory environment for non-invasive glucose devices continues to be challenging. The UFIT TEN-20 continues to require considerable resources for specific development prior to its general release. The Company will continue its development efforts to get the UFIT TEN-20 ready for release but anticipates delays that could extend past the end of this fiscal year.

The Company has also taken steps to reduce operating expenses through the reduction of certain expenditures and non-core headcount. The Company will continue to support the UFIT and Healthanywhere product portfolios and maintain its manufacturing, sales, technical support, clinical support and marketing capabilities. As part of the announced changes, Dr. Radu Leca has resigned as President and a Director of the Company but will be engaged as a scientific consultant that will focus his efforts towards getting the UFIT TEN-20 ready for launch. The position of President will not be filled at present. The day-to-day responsibilities of the President's role shall be assumed by Dr. Scott Jenkins, CEO of the Company. The Company extends its appreciation to Dr. Leca for all of his contributions to the Company as President.

The Board of Directors has initiated a process to review strategic alternatives, which may include, but are not limited to, a spin-off of certain assets, the sale of part of Biosign's assets and/or a merger or acquisition in an effort to maximize shareholder value.

"The Board of Directors and management are committed to maximizing value for shareholders" said Dr. Scott Jenkins, CEO of Biosign. "We are disappointed with the need to delay the launch of the UFIT TEN-20 but in light of both economic and general market conditions, we believe it more appropriate to focus on immediate revenue generating activities. We also believe that this is the right time for us to explore our strategic alternatives in an effort to maximize the value of the investment in our technology platform."

The Company does not intend to disclose developments with respect to the strategic review process unless and until the Board of Directors has approved a definitive transaction or strategic option, unless otherwise required by law.

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, life style, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

[in2lite]

Starting to follow. One to watch.

Stock Exchange » TSX-V:BIO
General Information
Corporation Name:
Biosign Technologies Inc.
230-175 Commerce Valley Drive West, Thornhill,ON L3T 7P6

Contact Person: Lorraine Grouios
Telephone: [phone] ext. 225
Facsimile: [phone]
Email: [e-mail]
Website: http://www.biosign.com